| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System |
Recent Updates
Recently added Catalysts
Assembly Biosciences, Inc.$27.4
-0.47 (-1.69%)
D 34Pipeline Score Overvalued Pharma · Commercial
Market Cap
471.46 M
EPS
-1.20
P/E Ratio
-20.39 $
Value Trade
4.40 M
SEC Financials
Q1 2026Dilution Risk
Revenue
8.21 M
R&D Expenses
14.90 M
Operating CF
-22.10 M
Total Assets
235.51 M
Total Liabilities
36.90 M
Equity
198.61 M
D/E Ratio
12,345
-5.34 %
Week
3.43 %
1 Month
8.87 %
3 Month
-21.99 %
6 Month
-41.97 %
5 Year
-93.87 %
All Time
Cash Data
Cash Position
226.60 M
Monthly Burn
7.37 M
Runway
28.9 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
169.99 K
52 Week Range
15.25 - 39.71
% held by Insiders
37.09 %
% held by Institutions
46.06 %
Enterprise Value
247.35 M
Total Shares
15.90 M
Short %
22.14 %
Float Shares
10.87 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Assembly Biosciences, Inc.
692Total events
7Upcoming
151Tier-1 (high impact)
2011 – 2027Coverage
Upcoming catalysts 7
Nov 15, 2026
T1Partnership / License
Potential collaboration agreement generating at least $75M non-dilutive capital triggers Class B warrant termination
TBD
T2Enrollment Complete
Enrollment completion of at least 200 patients for Phase 2 study of ABI-5366 vs valacyclovir triggers Class A warrant expiration
TBD
T2Timing Guidance
Complete data from Phase 1a expected to be submitted for presentation at future scientific meetings
TBD
T2Oral Presentation
Data from Phase 1b trial to be submitted for presentation at future scientific meetings
Event history 685
Jun 8, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
Jun 3, 2026
Jun 2026
◆Timing GuidancePresentation
Gilead's development plan and budget for herpesvirus program; opt-in decision by mid-2026
May 27, 2026
◆Poster PresentationABI-6250Presentation
Poster presentation of topline Phase 1a data on ABI-6250 at EASL Congress 2026
hepatitis delta virus (HDV)source ↗
May 26, 2026
▼Equity OfferingCorporate
Closing of underwritten registered offering of common stock and pre-funded warrants with full exercise of underwriters' option
May 22, 2026
▼Equity OfferingCorporate
Pricing of $100 million offering of common stock and pre-funded warrants
May 22, 2026
▲Trial CompletionABI-6250Trial
Phase 1a clinical trial completed in healthy participants
healthy participantssource ↗
May 22, 2026
◆Pre IND MeetingABI-6250FDA Meeting
Pre-IND meeting with FDA for ABI-6250 in cholestatic liver diseases
cholestatic liver diseases (PBC and PSC)source ↗
May 13, 2026
◆Oral PresentationPresentation
Presentation at BofA Securities 2026 Global Health Care Conference
Apr 21, 2026
◆Late-BreakerABI-1179Presentation
Late-breaker poster presentation on interim results from Phase 1b study of ABI-1179 at ESCMID Global 2026
recurrent genital herpessource ↗
Apr 20, 2026
◆Oral PresentationABI-5366Presentation
Oral presentation of Phase 1b data for ABI-5366 at ESCMID Global 2026
recurrent genital herpessource ↗
Apr 18, 2026
◆Poster PresentationABI-5366Presentation
Poster presentation on virologic analyses following treatment with ABI-5366 at ESCMID Global 2026
recurrent genital herpessource ↗
Drug Pipeline Intelligence
D34
Pipeline Score $275M
Pipeline ValueOvervalued
Valuation Signal9
Drugs Scored0.6x
rNPV / MCap Top 46%
Micro Cap (rank 493 of 911)
Percentile RankAssembly Biosciences, Inc. faces pipeline headwinds (34/100), with $688M risk-adjusted pipeline value, led by ABI-H0731 in Chronic Hepatitis B (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABI-H0731 Small molecule | Chronic Hepatitis B | Phase 2 | NCT03109730 | 21% | $193M | COMPLETED | 222 | - | - | Jun 12, 2018 | - | Jul 6, 2018 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ABI-1179 | recurrent genital herpes | Phase 1b | 2025-12-08 | 98% reduction in HSV-2 shedding rate; 91% reduction in virologically confirmed genital lesion rate; >99% reduction in high viral load shedding rate Read More | Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Read More | |
ABI-1179 | recurrent genital herpes | Phase 1b | 2025-12-08 | 98% reduction in HSV-2 shedding rate; 91% reduction in virologically confirmed genital lesion rate; >99% reduction in high viral load shedding rate Read More | Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Read More | |
ABI-1179 | recurrent genital herpes | Phase 1b | 2025-12-08 | 98% reduction in HSV-2 shedding rate; 91% reduction in virologically confirmed genital lesion rate; >99% reduction in high viral load shedding rate Read More | Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ASMB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ASMB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ASMBAssembly Biosciences Announces Upcoming June 2026 Investor Conference Presentations
Assembly Biosciences announced that its senior management will participate in fireside chats at two upcoming investor conferences: Jefferies 2026 Global Healthcare Conference on June 3, 2026, and Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The company is dedicated to developing therapeutics for serious viral and liver diseases. A replay of the webcasts will be available after each event.
Read more →ASMBAssembly Biosciences Announces Upcoming Investor Conference Presentations
Assembly Biosciences announced that its senior management will participate in fireside chats at two upcoming investor conferences: the Jefferies 2026 Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8. These events aim to enhance investor engagement and showcase the company's commitment to developing therapeutics for serious viral and liver diseases.
Read more →ASMBAssembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Assembly Biosciences has successfully closed its underwritten offering of 3,924,624 shares of common stock, raising approximately $115 million. The offering included the full exercise of the underwriters' option to purchase additional shares. The funds will be utilized for clinical development and general corporate purposes. The company faces risks related to collaboration benefits and clinical study timelines.
Read more →ASMB▲ +6.9%on this newsshared move
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
Assembly Biosciences is expanding the clinical development of ABI-6250 into cholestatic liver diseases, specifically targeting primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). This follows a completed Phase 1a study and aims to address significant unmet medical needs in these conditions. The company plans to initiate a Phase 2 study in Q1 2027, pending regulatory feedback.
Read more →ASMB▲ +6.9%on this newsshared move
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
Assembly Biosciences has announced the pricing of a $100 million offering of common stock and pre-funded warrants. The offering includes 3,358,602 shares priced at $26.50 each, with participation from significant investors such as Gilead Sciences. Proceeds will support clinical development and general corporate purposes, with the offering expected to close by May 26, 2026.
Read more →ASMBAssembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
Assembly Biosciences announced that it will present topline Phase 1a data on ABI-6250, an oral hepatitis D virus entry inhibitor, at the EASL Congress 2026. The data will support the company's plan to advance into a Phase 2 study by the end of the year. The presentation will cover safety, pharmacokinetics, and pharmacodynamics from a randomized, blinded study.
Read more →ASMBAssembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
Assembly Biosciences, a biotechnology firm, announced that its Chief Medical Officer, Anuj Gaggar, will present at the Bank of America Securities 2026 Global Health Care Conference on May 13, 2026. The presentation will focus on the company's innovative therapeutics aimed at serious viral diseases. A live webcast of the event will be available on their website.
Read more →ASMBAssembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Assembly Biosciences reported its first quarter 2026 financial results, highlighting the completion of Phase 1b studies for ABI-5366 and ABI-1179, as well as chronic toxicology studies for ABI-6250. The company anticipates initiating Phase 2 for ABI-6250 by Q4 2026. CEO Jason Okazaki noted ongoing progress and plans to evaluate Gilead's development plan for their herpesvirus program by mid-2026.
Read more →ASMBAssembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
Assembly Biosciences announced positive Phase 1b clinical data for ABI-5366 and ABI-1179, which are HSV helicase-primase inhibitors for recurrent genital herpes. The data will be presented at the ESCMID Congress in April 2026, with ABI-5366 featured in an oral presentation. ABI-1179's data will be presented as a late-breaker poster, highlighting its potential as a long-acting treatment.
Read more →ASMBAssembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
Assembly Biosciences reported its year-end 2025 financial results, highlighting a successful licensing agreement with Gilead for its helicase-primase inhibitor program following positive Phase 1b data. The company anticipates initiating Phase 2 trials for ABI-6250 by the end of 2026. CEO Jason Okazaki expressed optimism about the company's scientific and financial positioning for 2026.
Read more →ASMBAssembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically
Assembly Biosciences reported positive interim results from Phase 1b studies on two investigational helicase-primase inhibitors, ABI-1179 and ABI-5366, for treating recurrent genital herpes. ABI-1179 showed a 98% reduction in HSV-2 shedding and a 91% reduction in genital lesion rates. ABI-5366 also demonstrated significant antiviral activity with 76% reduction in virus shedding. Both treatments were found to be well-tolerated, paving the way for potential Phase 2 trials in the future.
Read more →ASMBAssembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
Assembly Biosciences reported strong third quarter results, highlighting positive interim data for ABI-5366 in treating recurrent genital herpes and the advancement of ABI-6250 to Phase 2 trials. The company raised $175 million in equity financing to support its pipeline. Additional data from ongoing studies is expected by year-end.
Read more →ASMBAssembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
Assembly Biosciences presented positive Phase 1b data for ABI-4334 at AASLD, showcasing its safety and potent antiviral effects against hepatitis B. The study reported significant declines in viral nucleic acids, indicating the drug's effectiveness. ABI-4334 is being evaluated in collaboration with Gilead Sciences for further development.
Read more →ASMBAssembly Biosciences Announces Upcoming Investor Conference Participation
Assembly Biosciences, Inc. (ASMB) announced its participation in two upcoming investor conferences. Chief Medical Officer Anuj Gaggar will present at the H.C. Wainwright Liver Disease Virtual Conference, while CEO Jason Okazaki and Dr. Gaggar will speak at the Guggenheim 2nd Annual Healthcare Innovation Conference. Both events will feature pre-recorded fireside chats available for on-demand viewing.
Read more →ASMBAssembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
Assembly Biosciences presented interim Phase 1b data for ABI-5366, a novel HSV helicase-primase inhibitor, at the IUSTI Congress. The data showed significant reductions in HSV-2 shedding and genital lesions compared to placebo, indicating the drug's potential effectiveness. The company plans to advance ABI-5366 to Phase 2 studies by mid-2026.
Read more →ASMB▲ +13%on this news
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
Assembly Biosciences has announced the pricing of a $175 million equity financing, which includes the sale of shares and warrants. The offering involves participation from both new and existing investors, including Gilead Sciences. The proceeds will be used for general corporate purposes, and the offering is expected to close on August 11, 2025, pending customary conditions.
Read more →ASMB▲ +13%on this newsshared move
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
Assembly Biosciences announced positive interim results from its Phase 1b study of ABI-5366, a helicase-primase inhibitor for recurrent genital herpes. The study showed a 94% reduction in HSV-2 shedding and genital lesion rates compared to placebo. The drug demonstrated a favorable safety profile, supporting further development into Phase 2 studies.
Read more →ASMB▲ +9.2%on this news· ran to +23% by day 3shared move
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
Assembly Biosciences has reported interim data from its Phase 1a clinical trial of ABI-6250, an oral entry inhibitor for hepatitis delta virus. The data show a mean half-life of four days, supporting a target for once-daily dosing, and dose-dependent elevations in biomarkers indicating target engagement. While the results are promising, there were some safety concerns, including ALT elevations in certain cohorts.
Read more →ASMBAssembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates – On track for proof-of-concept Phase 1b data this no later than this fall in participants with recurrent genital herpes for lo
Assembly Biosciences reported its second-quarter 2025 financial results, highlighting positive developments such as proof-of-concept Phase 1b data expected in fall 2025 for HSV candidates. The company reported strong topline results from a study of ABI-4334 for chronic hepatitis B. Additionally, interim data for ABI-6250 indicated promising biomarker engagement, while the company presented clinical findings at recent conferences. However, a net loss indicates underlying financial challenges.
Read more →ASMB▲ +5.1%on this news
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
Assembly Biosciences presented Phase 1a clinical data for its HSV helicase-primase inhibitors, ABI-5366 and ABI-1179, at the STI & HIV 2025 World Congress and the International Herpesvirus Workshop. The data suggest potential improvements in treatment regimens for recurrent genital herpes, with interim Phase 1b data expected in fall 2025. Both candidates are currently in clinical evaluation.
Read more →ASMBAssembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
Assembly Biosciences has initiated the Phase 1b portion of its clinical trial for ABI-1179, a long-acting helicase-primase inhibitor targeting recurrent genital herpes. The study will assess safety and antiviral activity over a 29-day treatment period. Interim data for ABI-1179 and its counterpart ABI-5366 is expected in fall 2025, following positive Phase 1a results.
Read more →ASMBAssembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B – Favorable safety and tolerability p
Assembly Biosciences announced positive topline results from its Phase 1b trial for ABI-4334, a next-generation capsid assembly modulator aimed at treating chronic hepatitis B virus infection. The trial demonstrated a favorable safety profile and significant reductions in HBV DNA levels in both 150 mg and 400 mg treatment cohorts. Results support the drug's effective inhibition of viral replication and opportunities for intensified mechanisms against the virus. Following these findings, further discussions are anticipated with Gilead Sciences regarding potential collaboration.
Read more →ASMBAssembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
Assembly Biosciences, a biotech firm specializing in treatments for serious viral diseases, will present at the Jefferies 2025 Global Healthcare Conference on June 4, 2025. The presentation will feature insights from CEO Jason Okazaki and CMO Anuj Gaggar. A live webcast of the event will be available, followed by a replay. The company emphasizes its commitment to developing innovative therapies while acknowledging potential financial and operational risks ahead.
Read more →ASMB▼ -6%on this news
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates – Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-act
Assembly Biosciences announced its financial results for Q1 2025, highlighting ongoing clinical studies for four antiviral candidates, with key data expected later this year. The CEO expressed pride in the company's progress and commitment to developing therapeutics for serious viral diseases. Financially, the company indicated a net loss and a significant cash position that will support operations into mid-2026. Upcoming clinical data and presentations at major conferences are set to showcase Assembly Biosciences' research activities.
Read more →ASMBAssembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
Assembly Biosciences presented promising data on its long-acting herpes simplex virus candidate ABI-5366 during the 2025 ESCMID Congress. The data confirms both clinical and preclinical results supporting ABI-5366's safety, tolerability, and potential for once-weekly or once-monthly oral treatment. Additionally, insights into genital herpes prevalence and treatment patterns highlight significant unmet needs in the management of the disease in the U.S. The ongoing Phase 1b trial aims to provide further insights into the drug's efficacy.
Read more →ASMBAss embly Biosciences Reports Year End 2024 Financial Results and Recent Highlights – Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipelin
Assembly Biosciences has reported its year-end 2024 financial results, highlighting rapid progress in its antiviral pipeline. The company anticipates important clinical data this year for four candidates, including ABI-5366 and ABI-1179, targeting recurrent genital herpes. Notably, positive interim data has been released for ABI-1179, indicating good tolerability for potential weekly dosing. Additionally, following a partnership with Gilead Sciences, the company received significant funding support to advance its clinical development programs.
Read more →ASMBAssembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
Assembly Biosciences has reported its financial results for the year ending December 31, 2024, highlighting significant advancements in its antiviral pipeline. The company anticipates interim Phase 1b efficacy data for two key candidates, ABI-5366 and ABI-1179, related to recurrent genital herpes in fall 2025. Additionally, positive early data from several other product candidates has been released, and a partnership with Gilead Sciences has bolstered their funding. Despite a net loss reported for the year, Assembly Biosciences maintains a projected cash runway into mid-2026.
Read more →ASMB▲ +7.9%on this news
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
Assembly Biosciences has initiated a Phase 1a clinical trial for its orally bioavailable entry inhibitor candidate, ABI-6250, targeting the Hepatitis Delta Virus. The study aims to evaluate the safety, tolerability, and pharmacokinetics of ABI-6250 in healthy participants, with data expected in Q3 2025. Currently, there are limited treatment options for chronic HDV, making this development significant as it could potentially simplify the treatment process. ABI-6250 has shown promising preclinical results, suggesting its efficacy in treating HDV infections.
Read more →ASMBAssembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes – ABI-1179 was well-tolerat
Assembly Biosciences has reported positive interim results from the Phase 1a clinical trial of ABI-1179, a helicase-primase inhibitor targeting recurrent genital herpes. The drug demonstrated a favorable safety profile and exceeded target plasma concentrations, supporting its potential for once-weekly oral administration. Following these optimistic results, Assembly Bio will move directly into the Phase 1b portion of the study, which will evaluate the drug in participants with recurrent genital herpes. Interim data for both ABI-1179 and another investigational drug, ABI-5366, is expected by fall 2025.
Read more →ASMBAssembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B – ABI-4334 was well-tolerated with a favorab
Assembly Biosciences has reported interim results from its Phase 1b trial of ABI-4334, a next-generation capsid assembly modulator for chronic hepatitis B. Initial findings indicate significant antiviral activity and a favorable safety profile in a 150 mg cohort. The company is currently enrolling participants for a 400 mg cohort, with results expected in the first half of 2025. ABI-4334 has not yet received global approval, emphasizing the need for further study to establish its efficacy and safety.
Read more →ASMB▲ +17%on this news
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
Assembly Biosciences has announced a $30.1 million equity investment and collaboration amendment with Gilead Sciences, which will support the advancement of its antiviral clinical pipeline. Gilead's investment includes $20.1 million in equity and $10 million in accelerated funding, increasing Gilead's ownership stake to 29.9%. The funding will help expedite the development of the hepatitis D virus candidate ABI-6250, with key clinical data expected in 2025. This collaboration marks a significant step forward for Assembly Bio as they focus on innovative antiviral therapies for serious viral diseases.
Read more →ASMB▲ +5.1%on this news
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates • Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent gen
Assembly Biosciences reported its Q3 2024 financial results, highlighting positive interim Phase 1a data for its HSV helicase-primase inhibitor candidate, ABI-5366. The company has initiated the Phase 1b trial for ABI-5366, targeting recurrent genital herpes, with interim results expected in early 2025. Two additional candidates, ABI-1179 and ABI-6250, are set to enter clinical trials by the end of the year, while the company reported a net loss of $9.6 million, reflecting ongoing development costs. Assembly's cash position is projected to fund operations through Q1 2026.
Read more →ASMB▼ -16.3%on this news
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 – ABI-5366 was well-tolerated, with a favorable safety profil
Assembly Biosciences has reported positive interim results from its Phase 1a clinical trial for ABI-5366, a helicase-primase inhibitor targeting recurrent genital herpes. The preliminary data reflects a favorable safety profile and pharmacokinetics that support weekly or monthly dosing regimens. The Phase 1b trial, which will further evaluate ABI-5366 in participants with recurrent genital herpes, is currently underway with recruitment for participants. The company aims to deliver interim results from this phase in the first half of 2025, potentially providing new treatment options for a condition with high unmet need.
Read more →ASMB▲ +6%on this news· ran to +18% by day 3
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates • Dosing initiated in healthy participants in Phase 1a/b trial for ABI-5366 targeting recurrent genital herpes, with interim Ph
Assembly Biosciences reported its financial results for Q2 2024, noting key advancements in its clinical trials. Dosing has begun for the Phase 1a/b trial of ABI-5366, aimed at treating recurrent genital herpes, with preliminary data anticipated in Q3 2024. Additionally, the company has initiated a Phase 1b trial for ABI-4334 targeting chronic HBV infections and plans to advance two additional candidates into the clinic by year-end. Despite a significant net loss of $11.2 million, the company secured $12.6 million through equity investments to support its antiviral portfolio into Q1 2026.
Read more →ASMBAssembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
Assembly Biosciences announced the presentation of new preclinical data for its investigational helicase-primase inhibitors, ABI-5366 and ABI-1179, at the International Herpesvirus Workshop. The data highlights ABI-5366's entry into Phase 1a/b trials, demonstrating promising efficacy against HSV types 1 and 2. ABI-1179 is set to enter clinical trials by the end of 2024, showing potential advantages over current treatments, including a higher barrier to drug resistance. Both candidates aim to improve management of recurrent genital herpes, which affects a significant portion of the population.
Read more →ASMBAssembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
Assembly Biosciences has initiated its Phase 1b clinical trial for ABI-4334, a next-generation capsid assembly modulator intended for the treatment of chronic hepatitis B virus infection. The trial, which aims to enroll up to 50 participants, will evaluate the drug's safety, pharmacokinetics, and antiviral activity over a 28-day period. ABI-4334 has previously demonstrated a favorable safety profile in Phase 1a studies, with high potency against HBV DNA replication and cccDNA formation. Interim results are expected later this year, providing insights into the drug's potential as a treatment option for chronic HBV infection.
Read more →ASMBAssembly Biosciences Announces $12.6 Million in Equity Financings Funding supports advancement of antiviral portfolio, including four candidates in clinical development, and extends cash runway into Q1 2026 Anticipated n
Assembly Biosciences has announced the completion of equity financings totaling approximately $12.6 million to support the advancement of its antiviral portfolio, including four clinical candidates. The funding will extend the company's financial runway into the first quarter of 2026. Key upcoming clinical milestones include interim data readouts for two of its candidates in the next 18 months. The firm has maintained a significant ownership stake for Gilead Sciences as a result of this financing arrangement.
Read more →ASMB▲ +6.5%on this news
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
Assembly Biosciences has commenced dosing the first participant in a Phase 1a/b clinical trial for its herpes simplex virus helicase-primase inhibitor candidate, ABI-5366. The trial aims to evaluate safety, tolerability, and pharmacokinetics in healthy participants, with the potential for effective treatment of recurrent genital herpes. Interim data from the trial is expected in Q3 2024 for Phase 1a and 1H 2025 for Phase 1b. The investigational new drug has shown promise in preclinical studies but remains unapproved worldwide.
Read more →ASMBAssembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
Assembly Biosciences presented new preclinical data for its hepatitis D virus entry inhibitor, ABI-6250, at the EASL Congress 2024. The data support the advancement of ABI-6250 into Phase 1 clinical studies, highlighting its effectiveness in inhibiting HDV infection and exhibiting selectivity for the NTCP target. This orally bioavailable candidate is expected to enter the clinic by the end of 2024, offering a potentially innovative treatment for chronic hepatitis D. However, ABI-6250 remains unapproved globally, requiring further validation for safety and efficacy.
Read more →ASMBAssembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
Assembly Biosciences, Inc. announced that it will present preclinical data for its pipeline programs at upcoming medical congresses. Key data on the helicase-primase inhibitors ABI-5366 and ABI-1179 for recurrent genital herpes will be shared at the International Herpesvirus Workshop in July 2024. Additionally, data on ABI-6250, an orally-bioavailable entry inhibitor for hepatitis D, will be presented at the EASL Congress™ 2024 in June. The presentations highlight the company's commitment to innovative therapeutics in viral diseases.
Read more →ASMBAssembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights • Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital herpes, and
Assembly Biosciences reported its first-quarter financial results for 2024, highlighting regulatory clearance for clinical trials of ABI-5366 and ABI-4334. Both trials are set to initiate by mid-2024, with interim data expected later this year. The company emphasized its solid financial health, having $113 million available to fund operations into late 2025. However, the company reported a net loss of $9.1 million in Q1 2024, though it is an improvement from the previous year's loss.
Read more →ASMBAssembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights • Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated
Assembly Biosciences reported its financial results for Q4 2023, highlighting plans for four candidates in clinical development by 2024. The company anticipates interim data from ABI-5366 and ABI-4334 by the end of the year. Assembly has also entered a partnership with Gilead Sciences to enhance its antiviral product pipeline. Financially, the company improved its cash position, projecting operational funding through the second half of 2025.
Read more →ASMBAssembly Biosciences Announces Effective Date of Reverse Stock Split – Assembly Bio common stock expected to begin trading on a split-adjusted basis on
Assembly Biosciences, Inc. has announced a 1-for-12 reverse stock split effective February 9, 2024, with shares expected to trade on a split-adjusted basis from February 12. This action aims to secure compliance with Nasdaq's minimum bid price requirement. The number of outstanding shares will be reduced from approximately 65.8 million to 5.5 million. Shareholder approval for the split was obtained at a special meeting held on January 31, 2024, indicating support for the company's strategic decisions.
Read more →ASMBAssembly Biosciences Announces Effective Date of Reverse Stock Split
Assembly Biosciences announced that a 1-for-12 reverse stock split will take effect on February 9, 2024. Following the split, the total number of outstanding shares will decrease from approximately 65.8 million to 5.5 million. The move is intended to help the company comply with Nasdaq's minimum bid price requirements, as approved by its stockholders on January 31, 2024. The common stock will begin to trade on a split-adjusted basis on February 12, 2024.
Read more →ASMBAssembly Biosciences Provides Anticipated Development Milestones for 2024
Assembly Biosciences announced the anticipated milestones for 2024, stating that four development candidates will likely enter clinical trials by year-end. Key candidates include ABI-5366 for recurrent genital herpes and ABI-4334 for chronic hepatitis B. The progress is bolstered by a partnership with Gilead Sciences, which is expected to enhance Assembly's antiviral portfolio. Initial clinical data from these candidates is also anticipated soon, marking significant advancements in their research efforts.
Read more →ASMBAssembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting
Assembly Biosciences presented new findings at The Liver Meeting on its antiviral therapeutics portfolio, emphasizing the potential of its oral small molecule IFNAR agonist program. Data from a poster indicated promising preclinical activity against hepatitis B and C viruses through IFN signaling activation. Additionally, a Phase 2 study on vebicorvir's combination therapy did not exhibit enhanced outcomes compared to other treatments, leading to the discontinuation of the drug's development.
Read more →ASMBAssembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Assembly Biosciences, Inc. announced the grant of stock options to its new Chief Medical Officer, Dr. Anuj Gaggar, as part of an inducement to accept the role. The grant includes 500,000 non-qualified stock options at an exercise price of $0.85 per share, with a vesting schedule of four years. This award was approved in accordance with Nasdaq Listing Rule 5635(c)(4) and highlights the company's efforts to attract key talent in the biotechnology sector. The options are granted from various incentive plans, which emphasizes the company's commitment to employee retention and strategic growth.
Read more →ASMBAssembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
Assembly Biosciences has appointed Dr. Anuj Gaggar as their new Chief Medical Officer, bringing extensive expertise in infectious diseases and antiviral programs. Dr. Gaggar's previous experience includes leading clinical research at Gilead Sciences, where he oversaw major antiviral drug development. He expressed enthusiasm for advancing Assembly Bio's innovative antiviral candidates, which are expected to enter clinical trials next year. The company's goal is to improve treatment options for patients with viral infections, particularly chronic hepatitis.
Read more →ASMBAssembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates - Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond - Now antici
Assembly Biosciences has reported strong progress in its Q3 2023 financial results alongside key corporate updates. The company has formed a long-term partnership with Gilead Sciences, aimed at developing innovative antiviral treatments for herpesviruses and hepatitis. With the new collaboration, Assembly Biosciences anticipates four development candidates to enter clinical studies by the end of 2024, backed by a $100 million investment from Gilead. The leadership was further strengthened with the appointment of Dr. Anuj Gaggar as chief medical officer.
Read more →ASMBAssembly Biosciences to Present New Data at AASLD The Liver Meeting
Assembly Biosciences is set to present new data at the upcoming AASLD The Liver Meeting in November 2023. The company will showcase preclinical data on its interferon-α receptor agonist program and oral presentation results from a Phase 2 study involving its core inhibitor vebicorvir, in combination with other therapies, for chronic hepatitis B. These studies aim to demonstrate the potential effectiveness of their antiviral approaches. Presentations will contribute to ongoing discussions among researchers and clinicians focused on hepatitis treatments.
Read more →ASMBAssembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
Assembly Biosciences has nominated ABI-6250 as a development candidate for chronic hepatitis D virus (HDV) infection. This orally bioavailable entry inhibitor has shown low nanomolar potency against HDV in preclinical studies and is expected to progress into clinical studies by the end of 2024. ABI-6250 aims to provide the first oral treatment option for HDV patients, who currently face limited therapeutic options, mainly requiring daily injections. The drug specifically inhibits NTCP, the receptor used for viral entry, which may significantly reduce liver injury in affected patients.
Read more →ASMB▼ -5.7%on this news
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
Assembly Biosciences is showcasing new preclinical data from its pipeline programs targeting hepatitis B virus (HBV) and hepatitis D virus (HDV) at the 2023 International HBV Meeting in Kobe, Japan. Highlights include progress in their oral entry inhibitor program and new data on the capsid assembly modulator ABI-4334, indicating its potential to prevent HBV DNA integration. Furthermore, the company is also presenting findings on small molecule interferon-alpha receptor agonists that may enhance tolerability when tackling HBV. Assembly Bio is optimistic about nominating a development candidate from its HBV/HDV entry inhibitor program later this year.
Read more →ASMBAssembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates - Herpesvirus candidate ABI-5366 anticipated to enter clinic in first half of 2024 - New data for several pipeline programs presented
Assembly Biosciences reported its financial results for the second quarter of 2023, highlighting optimistic developments in its pipeline. The company is preparing to enter clinical trials for its herpesvirus candidate ABI-5366 in early 2024 and is progressing towards additional development candidate nominations. Financially, the company noted a decrease in cash and an increased net loss during the quarter, but maintaining operations through Q3 2024 is projected. Strong preclinical data was featured at various scientific conferences, emphasizing the advancement of their antiviral research programs.
Read more →ASMBAssembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
Assembly Biosciences has presented new data on ABI-5366, a long-acting antiviral candidate for herpes simplex virus, at the 47th Annual International Herpesvirus Workshop. The preclinical data indicate potent antiviral activity against HSV-1 and HSV-2, with favorable pharmacokinetics and safety profile. Assembly Bio plans to initiate GLP toxicology studies and expects to enter clinical trials in the first half of 2024. The findings suggest significant advancements for patients suffering from high-recurrence genital herpes.
Read more →ASMBAssembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
Assembly Biosciences presented new data on its hepatitis D and B virus antiviral pipeline at the EASL International Liver Congress 2023. The presentations highlighted advancements in the company's entry inhibitors and novel core inhibitors that show promise in achieving deep reductions in viral replication. Particularly, two investigational core inhibitors demonstrated improved potency and tolerability in preliminary studies. There is optimism about the potential of these agents to enhance treatment outcomes for patients with chronic hepatitis B and D infections.
Read more →ASMBAssembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
Assembly Biosciences will present new data from its antiviral pipeline focused on herpesvirus, hepatitis B, and hepatitis D at two upcoming international congresses. The International Herpesvirus Workshop will showcase the first data on ABI-5366, a long-acting HSV helicase inhibitor, while the EASL International Liver Congress will feature findings on HBV and HDV drugs, including potent next-generation core inhibitors. The presentations highlight the company's commitment to addressing significant unmet needs in viral disease treatment.
Read more →ASMBAssembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced that CEO Jason Okazaki and CSO William Delaney will present at the 2023 Jefferies Healthcare Conference on June 7, 2023. The live webcast will be accessible on the company's website. The company focuses on developing antiviral therapeutics for serious viral diseases, including hepatitis B and herpesvirus. However, there are associated risks including financial resource management and uncertainties concerning clinical studies.
Read more →ASMBAssembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights - Herpesvirus candidate ABI-5366 progressing towards IND and planned to enter the clinic in the first half of 2024 - Additional deve
Assembly Biosciences reported its financial results for the first quarter of 2023, highlighting the advancement of its herpesvirus candidate ABI-5366 towards clinical trials expected to begin in the first half of 2024. The company also plans to nominate an additional development candidate later this year and presented promising data for its hepatitis B core inhibitors. While the financial outlook shows reduced losses from the previous year, the decrease in cash reserves could pose challenges. Assembly Bio's strategy includes evaluating partnerships for its core inhibitors while focusing resources on antiviral programs with shorter paths to clinical proof of concept.
Read more →ASMBAssembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update • Phase 1a clinical dat
Assembly Biosciences reported encouraging results from the Phase 1a trial of its next-generation HBV core inhibitor ABI-4334, indicating strong antiviral activity and potential for inhibiting cccDNA formation. The company plans to explore partnerships for its core inhibitor portfolio while focusing on antiviral programs with near-term clinical impact, such as ABI-5366 for genital herpes. The estimated cash runway extends into Q3 2024, supporting ongoing studies and potential new clinical trials.
Read more →ASMBAssembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights • Prioritization of core inhibitor candidate ABI-4334 and pausi
Assembly Biosciences provided an update on its core inhibitor pipeline, focusing on candidates ABI-4334 and ABI-H3733. The company decided to prioritize ABI-4334 based on its greater potency and the strong clinical profile observed in initial studies, while pausing ABI-H3733 due to toxicology concerns. With Phase 1a data for ABI-4334 expected in April 2023, Assembly continues to advance its pipeline and expand with a herpesvirus candidate, ABI-5366, slated for clinical trials in 2024. However, the concerns regarding ABI-H3733's toxicology may impact its future development timeline.
Read more →ASMBAssembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes −ABI-5366 Demonstrates Favorable Profile for a Long-
Assembly Biosciences has selected ABI-5366 as its first herpesvirus development candidate, aimed at treating high-recurrence genital herpes. Preclinical studies indicate that ABI-5366 could function as a long-acting therapeutic with exceptional pharmacokinetics, leading to improved patient outcomes. The candidate is poised for IND-enabling studies, with expectations for a filing in the first half of 2024. Assembly Bio is responding to a significant medical need, as there have been no new treatments approved for this condition in recent decades.
Read more →ASMB▲ +14.5%on this news
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334  In initial ABI-H3733 cohort of 50 mg in
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334 In initial ABI-H3733 cohort of 50 mg in 28-day Phase 1b study, six of eight HBV patients on treatment reach
Read more →ASMB▲ +8.2%on this news
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
Healthy volunteer study will inform development of 4334 for treatment of hepatitis B virus SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational ther
Read more →ASMB▼ -7.4%on this news
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation Phase 1a Trial of Next-Generation Core Inhibitor, ABI-4334, Now Underway Following C
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation Phase 1a Trial of Next-Generation Core Inhibitor, ABI-4334, Now Underway Following Clinical Trial Application (CTA) Clearance SOUTH SAN FRANCI
Read more →ASMB▼ -5%on this news· ran to -18% by day 3shared move
Assembly Biosciences Presents New Data at AASLD The Liver Meeting Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV
Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into clinical studies First data presented on preclinical characterization of potent, orally bioavailable viral entry inhibit
Read more →ASMBAssembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting
Four poster presentations, including two late breaking, highlight breadth and promise of virology portfolio Data demonstrating preclinical activity of next-generation core inhibitor ABI-4334 against hepatitis B virus supports planned advancement into clinical studies before year
Read more →ASMBAssembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor Dr. McHutchison will continue to provide strategic counsel as board member and
Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor Dr. McHutchison will continue to provide strategic counsel as board member and chairman of the Science & Technology Committee of the board
Read more →ASMBAssembly Biosciences to Host Webcast on August 31, 2022, Introducing Two New Research Programs Targeting Recurrent HSV-2 Infection and Transplant-Associated Herpesvirus Diseases
- Renowned virologist, Nobel laureate and Assembly Bio board member, Sir Michael Houghton, PhD, will join company leadership for the discussion - SOUTH SAN FRANCISCO, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnol
Read more →ASMBAssembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., August 9, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational thera
Read more →ASMBAssembly Biosciences Announces Program Reprioritization and Organizational Update - Discontinues clinical development of vebicorvir, Assembly Bio's first-generation core inhibitor, based on interim efficacy data from ong
Assembly Biosciences Announces Program Reprioritization and Organizational Update - Discontinues clinical development of vebicorvir, Assembly Bio's first-generation core inhibitor, based on interim efficacy data from ongoing combination clinical studies - Advancing next-generat
Read more →ASMBAssembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022
SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced data fr
Read more →ASMBAssembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL’s International Liver Congress™ 2022
SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that si
Read more →ASMBAssembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced the ini
Read more →ASMB▲ +7.4%on this news· ran to +27% by day 3
Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeu
Read more →ASMB▲ +12.3%on this news
Assembly Biosciences to Highlight New Research Program for HBV/HDV Entry Inhibition in Webcast on March 31, 2022
SOUTH SAN FRANCISCO, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, will host a webcast on Thursday, March
Read more →ASMBAssembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights
Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeut
Read more →ASMBAssembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that John McHutchison, A
Read more →ASMBAssembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced grants of stock options
Read more →ASMBAssembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that John McHutchison, A
Read more →ASMBAssembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones
Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones SOUTH SAN FRANCISCO, Calif., Jan. 4, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B
Read more →ASMBAssembly Biosciences Presents New Data at AASLD The Liver Meeting™ Highlighting the Progress of its HBV Core Inhibitor Portfolio
Newly selected preclinical core inhibitor candidate, ABI-4334, demonstrates single-digit nanomolar potency against both pgRNA encapsidation and cccDNA formation ABI-H3733 shows favorable pharmacokinetics and safety in Phase 1a study; Phase 1b study expected to begin in 2022 Veb
Read more →ASMBAssembly Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
Assembly Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., Nov. 4, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting he
Read more →ASMBAssembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that clinical and preclinical data from its HBV c
Read more →ASMBAssembly Bio Announces October Conference Participation
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), announced participation in the below upcoming conferences focused
Read more →ASMBAssembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158 --Decision follows observation of elevated alanine transaminase (ALT) levels in Phase 2 study --Company will focus on advancing ongoing tri
Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158 --Decision follows observation of elevated alanine transaminase (ALT) levels in Phase 2 study --Company will focus on advancing ongoing triple combination studies and earlier pipeline candidates S
Read more →ASMBAssembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced it has selected a fourth core inhibitor candidate
Read more →ASMBAssembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights
Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, CA, August 5, 2021 -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (H
Read more →ASMB▲ +5.5%on this newsshared move
Assembly Bio Announces Key Promotions to Leadership Team
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced the promotions of Jason Okazaki to chief operati
Read more →ASMBNobel Laureate Dr. Michael Houghton Appointed to Assembly Biosciences Board of Directors -- Esteemed academic and industry virologist discovered hepatitis C virus (HCV); brings 40+ years of scientific and drug developmen
Nobel Laureate Dr. Michael Houghton Appointed to Assembly Biosciences -- Esteemed academic and industry virologist discovered hepatitis C virus (HCV); brings 40+ years of scientific and drug development experience -- SOUTH SAN FRANCISCO, CA, July 20, 2021 -- Assembly Bioscience
Read more →ASMBAssembly Biosciences Presents Data from HBV Core Inhibitor Programs at the International Liver Congress™ EASL 2021
SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced data from its three clinical-stage core inhibitor
Read more →ASMBAssembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021
SOUTH SAN FRANCISCO, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that three abstracts have been accepted for prese
Read more →ASMBAssembly Biosciences Reports First Quarter 2021 Financial Results and Recent Updates
Assembly Biosciences Reports First Quarter 2021 Financial Results and Recent Updates SOUTH SAN FRANCISCO, CA, May 6, 2021 -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), to
Read more →ASMBAssembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus - Trial will evaluate Assembly's core inhibitor candidate, vebicorvi
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus SOUTH SAN FRANCISCO, Calif., and WARMINSTER, Pa. -- Feb. 26, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB)
Read more →ASMBAssembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection
- Prioritizing next generation, more potent core inhibitors, triple combinations with complementary mechanisms of action, and expanding research programs to advance multiple candidates against novel targets - Extends cash runway into 2023 - Company to host conference call today
Read more →ASMBAssembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights
Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, CA, February 25, 2021 -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepa
Read more →ASMBAssembly Bio Announces Upcoming Investor Events
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced two upcoming investor events: 2021 Key Objective
Read more →ASMBAssembly Biosciences to Wind-Down Microbiome Program Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio
Assembly Biosciences to Wind-Down Microbiome Program Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio SOUTH SAN FRANCISCO, Calif., December 8, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotec
Read more →ASMBAssembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the a
Read more →ASMBAssembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option Agreement to Develop a Novel Class of HBV Core Protein Modulators
Assembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option Agreement to Develop a Novel Class of HBV Core Protein Modulators SOUTH SAN FRANCISCO, Calif., November 16, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door Pharmaceuticals, LL
Read more →ASMBAssembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™
- Data show longer-term, differentiated safety profile of vebicorvir and the importance of HBV pregenomic (pg) RNA as a key biomarker, as well as highlight Assembly Bio’s core inhibitor clinical pipeline - SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Assembly B
Read more →ASMBAssembly Biosciences Reports Third Quarter 2020 Financial Results and Business Update
Assembly Biosciences Reports Third Quarter 2020 Financial Results and SOUTH SAN FRANCISCO, CA, November 5, 2020 -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases
Read more →ASMBAssembly Biosciences Provides Update on the Ongoing Phase 2 Extension Study of Vebicorvir in Patients with Chronic Hepatitis B Virus Infection
- HBV field’s first core inhibitor combination study to assess off-treatment response has not achieved a meaningful rate of sustained virologic response - - Vebicorvir Phase 3 registrational program remains on track to initiate in H1 2021 for chronic suppressive therapy - - Ass
Read more →ASMBAssembly Biosciences Appoints Gina Consylman to Board of Directors
Assembly Biosciences Appoints Gina Consylman to Board of Directors SOUTH SAN FRANCISCO, Calif., October 20, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (
Read more →ASMBAssembly Biosciences CEO Dr. John McHutchison Named Recipient of the Prestigious Advance 2020 Global Impact Award
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that
Read more →ASMBAssembly Biosciences Announces October Conference Participation
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, announced participati
Read more →ASMBSection 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward-looking information within the meaning of Canadian securities laws (collectively, "forward-looking statements"
Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection SOUTH SAN FRANCISCO, Calif., and WARMINSTER, Penn., Augu
Read more →ASMBAssembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection
SOUTH SAN FRANCISCO, Calif. and WARMINSTER, Pa., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that the companies have entered into a clinical collaboration agreement to evaluate Assem
Read more →ASMBAssembly Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights
Assembly Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, CA, August 5, 2020 -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (H
Read more →ASMBAssembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly's Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection -- BeiGene acquires exclusive deve
Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly's Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection -- BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABI-H215
Read more →ASMBAssembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection
SOUTH SAN FRANCISCO, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome today announced that t
Read more →ASMBAssembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection
SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the i
Read more →ASMBAssembly Biosciences Regains Worldwide Rights to Microbiome Gastrointestinal Development Programs
-- Process to explore strategic alternatives underway -- SOUTH SAN FRANCISCO, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and dise
Read more →ASMBAssembly Biosciences Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced grant
Read more →ASMBAssembly Biosciences Announces Management Transition
-- Expert Virologist and Biologist William Delaney, PhD joins as Chief Scientific Officer, Virology -- -- EVP and CSO of Virology Operations Richard Colonno, PhD to retire -- SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB)
Read more →ASMBAssembly Biosciences to Present During the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that J
Read more →ASMBAssembly Biosciences Announces Move to Virtual-Only Annual Meeting of Stockholders on June 11, 2020
SOUTH SAN FRANCISCO, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced that it will hold its 2020 Annual Meeting of Stockholders (Annual Meeting) solely by means of remote communication (i.e., a virtual-only stockholder meeting). T
Read more →ASMBAssembly Biosciences Reports Updates on Corporate Progress and First Quarter 2020 Financial Results -- Advancing the development of three clinical-stage core inhibitor candidates in HBV portfolio -- -- Cash position of $
Assembly Biosciences Reports Updates on Corporate Progress and First Quarter 2020 Financial Results -- Advancing the development of three clinical-stage core inhibitor candidates in -- Cash position of $249 million projected to fund operations into 2022 -- -- Company to host
Read more →ASMBAssembly Biosciences Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced grants
Read more →ASMBAssembly Biosciences to Host Conference Call and Webcast to Review HBV Portfolio Progress
SOUTH SAN FRANCISCO, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced plan
Read more →ASMBAssembly Biosciences Appoints Jason Okazaki as Chief Legal and Business Officer
SOUTH SAN FRANCISCO, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the
Read more →ASMBAssembly Biosciences Reports Fourth Quarter and Year End 2019 Financial Results
Assembly Biosciences Reports Fourth Quarter and Year End 2019 Financial Results SOUTH SAN FRANCISCO, Calif., March 4, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis
Read more →ASMBAssembly Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that
Read more →ASMBAssembly Biosciences Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today announced the closing of its previously announced underwritten public offering of 6,287,878 shares of its common stock to the public at $16.50 per share, w
Read more →ASMBAssembly Biosciences Announces Pricing of $125 Million Public Offering
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today announced the pricing of an underwritten public offering of 5,151,515 shares of its common stock to the public at $16.50 per share. In addition, and in lie
Read more →ASMBAssembly Biosciences Announces Proposed Public Offering of Common Stock
Assembly Biosciences Announces Proposed Public Offering of Common Stock SOUTH SAN FRANCISCO, Calif., December 11, 2019 (GLOBE NEWSWIRE) Assembly Biosciences, Inc. (Nasdaq: ASMB) ( Assembly ), today announced that it intends to offer and sell, subject to market and other conditi
Read more →ASMBAssembly Biosciences Announces Plenary Lecture at HEP DART 2019
SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that
Read more →ASMBAssembly Biosciences Announces Presentation at Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that
Read more →ASMBAgenda and Speakers on Today's Call Agenda Introductions and Safe Harbor Overview of ASMB vision and HBV core inhibitor portfolio Review of HBV data from AASLD ABI-H0731 Final 24 week data from Study 201 and 202 Interim
AASLD 2019 Review November 11, 2019 Agenda and Speakers on Today's Call Agenda Introductions and Safe Harbor Overview of ASMB vision and HBV core inhibitor portfolio Review of HBV data from AASLD ABI-H0731 Final 24 week data from Study 201 and 202 Interim long-term data from St
Read more →ASMBAssembly Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights
Assembly Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., November 7, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targetin
Read more →ASMBAssembly Biosciences Appoints Luisa Stamm, MD, PhD, as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the a
Read more →ASMBAssembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a gra
Read more →ASMBAssembly Biosciences Appoints Thomas J. Russo as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the a
Read more →ASMBAssembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a gra
Read more →ASMBAssembly Biosciences Announces Appointment of John McHutchison, AO, MD, as President and Chief Executive Officer
Dr. McHutchison is a world-renowned hepatologist, gastroenterologist, and anti-viral drug developer He led the research and development of five marketed therapies for chronic hepatitis B and chronic hepatitis C Succeeds Derek Small, Co-Founder of Assembly Biosciences, who will
Read more →ASMBAssembly Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights
Assembly Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, August 5, 2019 - Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV
Read more →ASMBAssembly Biosciences Announces First Patient Dosed with ABI-M201 in Phase 1b Clinical Trial for Mildly to Moderately Active Ulcerative Colitis
First oral microbiome biologic drug candidate from Assembly’s novel microbiome platform to enter clinical trials in patients ABI-M201 utilizes Assembly’s proprietary and patented Gemicel® capsule-in-capsule delivery system for targeted delivery into the GI tract SAN FRANCISCO,
Read more →ASMBAssembly Biosciences Announces Participation in the Microbiome Movement Drug Development Summit
SAN FRANCISCO, June 25, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced participation in th
Read more →ASMBAssembly Biosciences Announces Presentation at International Association for the Study of the Liver Congress and Update on HBV Program in China
SAN FRANCISCO, June 21, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Richard Colonn
Read more →ASMBAssembly Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights
Assembly Biosciences Reports First Quarter 2019 Financial Results and Recent Highlights SAN FRANCISCO, May 9, 2019 - Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and dise
Read more →ASMBAssembly Biosciences Announces Changes to Senior Leadership Team
Assembly Biosciences Announces Changes to Senior Leadership Team SAN FRANCISCO, May 2, 2019 - Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with th
Read more →ASMBAssembly Biosciences Presents Interim Data from Two Phase 2a Studies of ABI-H0731 in HBV-Infected Subjects in a Late-Breaker Oral Session at EASL 2019
- Favorable safety and tolerability profile - Superior antiviral activity with ABI-H0731 in combination with nucleos(t)ide therapies - Selected for inclusion in “Best of ILC” presentation - Company to host conference call Monday, April 15, 2019 at 8am EDT SAN FRANCISCO, April
Read more →ASMBAssembly Biosciences Presents Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019
Phase 1a study of ABI-H2158 demonstrated safety, tolerability and achievement of target liver concentrations ABI-H3733 demonstrated enhanced potency in preclinical studies HBV cccDNA shown to have a limited half-life, suggesting potential for curative treatment regimen Interim
Read more →ASMBAssembly Biosciences Announces Multiple Abstracts Highlighting HBV Core Inhibitor Portfolio Accepted for Oral and Poster Presentations at EASL 2019
SAN FRANCISCO, March 27, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the acceptance of
Read more →ASMBAssembly Biosciences to Participate in the Jefferies 2019 HBV Summit
SAN FRANCISCO, March 13, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Derek Small,
Read more →ASMBAssembly Biosciences Reports Fourth Quarter and Year End 2018 Financial Results
Assembly Biosciences Reports Fourth Quarter and Year End 2018 Financial Results SAN FRANCISCO, February 28, 2019 - Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseas
Read more →ASMBAssembly Biosciences Announces Completion of Enrollment in Two Phase 2a Studies with ABI-H0731 for Chronic Hepatitis B Virus
SAN FRANCISCO, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced completion of patie
Read more →ASMBAssembly Biosciences Presents Final Results of Phase 1b Study of ABI-H0731 at 2018 AASLD
First Presentation of HBV RNA Reduction Data, a Distinguishing Feature of Core Inhibitors SAN FRANCISCO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B v
Read more →ASMBAssembly Biosciences Announces Third Quarter 2018 Financial Results and Provides HBV Program Update - ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Data Continues to be Anticipated in 1H 2019 - ABI-H215
Assembly Biosciences Announces Third Quarter 2018 Financial Results and Provides HBV Program Update - ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Data Continues to be Anticipated in 1H 2019 - ABI-H2158 Phase 1a Study Initiated - ABI-H3733 Nominated as Thir
Read more →ASMBAssembly Biosciences Announces November Conference Participation
SAN FRANCISCO, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced participation at va
Read more →ASMBAssembly Biosciences Announces Oral Presentation at 2018 AASLD
SAN FRANCISCO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that the company wi
Read more →ASMBAssembly Biosciences to Present at Upcoming Investor Conferences
SAN FRANCISCO, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), today announced that the company will be participating in the following upcoming investor conferences in September: Baird Global Healthcare Conference: Uri Lopatin, MD, Chief Medical Offi
Read more →ASMBAssembly Biosciences Announces Second Quarter 2018 Financial Results - ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Initial Data Continues to be Anticipated in H1 2019 - Strong Balance Sheet Provides S
Assembly Biosciences Announces Second Quarter 2018 Financial Results - ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Initial Data Continues to be Anticipated in H1 2019 - Strong Balance Sheet Provides Significant Runway SAN FRANCISCO and INDIANAPOLIS, Augus
Read more →ASMBAssembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H0731 for the Treatment of Hepatitis B Virus Infection
INDIANAPOLIS and SAN FRANCISCO, July 25, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABI-H0731 for the treatment of patients with chronic Hepatitis B infec
Read more →ASMBAssembly Biosciences Announces the Closing of its Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
INDIANAPOLIS and SAN FRANCISCO, July 16, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock to the public at $36.00 per share,
Read more →ASMBAssembly Biosciences Announces Pricing of $144 Million Offering of Common Stock
INDIANAPOLIS and SAN FRANCISCO, July 11, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) (“Assembly”), today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock to the public at $36.00 per share. The offering is expec
Read more →ASMBAssembly Biosciences Announces Proposed Underwritten Offering of Common Stock INDIANAPOLIS and
Assembly Biosciences Announces Proposed Underwritten Offering of Common Stock INDIANAPOLIS and SAN FRANCISCO - July 10, 2018 - Assembly Biosciences, Inc. (Nasdaq:ASMB) ("Assembly"), today announced that it intends to offer and sell, subject to market and other conditions, 3,0
Read more →ASMBAssembly Biosciences Initiates Two Phase 2a Trials of ABI-H0731 for the Treatment of Hepatitis B Virus Infection Key aim is to demonstrate that core inhibitor therapy combined with standard of care antivirals can offer c
Assembly Biosciences Initiates Two Phase 2a Trials of ABI-H0731 for the Treatment of Hepatitis B Virus Infection Key aim is to demonstrate that core inhibitor therapy combined with standard of care antivirals can offer curative potential for HBV INDIANAPOLIS and SAN FRANCISCO
Read more →ASMBR&D Day Hepatitis B Program
1 R&D Day Hepatitis B Program June 20, 2018 NASDAQ: ASMB 2018 Assembly Biosciences, Inc. 2 2 CAUTIONARY NOTE REGARDING FORWARD - LOOKING STATEMENTS The information in this presentation contains estimates and other forward - looking statements regarding future events, including s
Read more →ASMBAssembly Biosciences to Host Research and Development Day on Wednesday, June 20, 2018
INDIANAPOLIS and SAN FRANCISCO, June 13, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live bioth
Read more →ASMBAssembly Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
INDIANAPOLIS and SAN FRANCISCO, June 08, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live biothe
Read more →ASMBAssembly Biosciences to Participate in Jefferies 2018 Global Healthcare Conference
INDIANAPOLIS and SAN FRANCISCO, June 04, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live bioth
Read more →ASMBAssembly Biosciences Announces First Quarter 2018 Financial Results INDIANAPOLIS and
Assembly Biosciences Announces First Quarter 2018 Financial Results INDIANAPOLIS and SAN FRANCISCO, May 7, 2018 - Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B viru
Read more →ASMBAssembly Biosciences Presents Positive Interim Data from Phase 1a and 1b Studies of ABI-H0731 in HBV Patients in a Late-Breaker Session at the EASL Conference
Robust antiviral activity observed in HBV patients Generally safe and well tolerated Planning underway for Phase 2a studies beginning summer 2018 Company to host conference call on Thursday, April 12th at 8am ET / 2pm CEST INDIANAPOLIS and SAN FRANCISCO, April 12, 2018 (GLOBE
Read more →ASMBAssembly Biosciences to Host Conference Call on April 12 to Review ABI-H0731 Interim Phase 1b Data in HBV Patients Featured in Late-Breaker Poster at EASL
INDIANAPOLIS and SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutic
Read more →ASMBAssembly Biosciences Appoints Jackie Papkoff, PhD, Senior Vice President, Chief Scientific Officer Microbiome
INDIANAPOLIS and SAN FRANCISCO, April 02, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutic
Read more →ASMBAssembly Biosciences Announces ABI-H0731 Phase 1b Interim Data Accepted as a Late-Breaker Poster at The International Liver Congress™ (EASL)
INDIANAPOLIS and SAN FRANCISCO, March 28, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutic
Read more →ASMBAssembly Biosciences Announces Additions to Management Team and Board of Directors Accomplished industry veterans further strengthen leadership team; Graham Cooper joins as CFO and COO and Helen S. Kim is appointed to Bo
Assembly Biosciences Announces Additions to Management Team and Board of Directors Accomplished industry veterans further strengthen leadership team; Graham Cooper joins as CFO and COO and Helen S. Kim is appointed to Board of Directors INDIANAPOLIS, March 12, 2018 - Assembl
Read more →ASMBAssembly Biosciences to Present at Cowen’s 38th Annual Healthcare Conference
INDIANAPOLIS, March 05, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders as
Read more →ASMBAssembly Biosciences to Participate in Leerink Partners 7th Annual Global Healthcare Conference
INDIANAPOLIS, , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders a
Read more →ASMBAssembly Biosciences to Present at the J.P. Morgan Healthcare Conference
INDIANAPOLIS, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders ass
Read more →ASMBAssembly Biosciences Appoints Sue Mahony, PhD to Board of Directors INDIANAPOLIS
Assembly Biosciences Appoints Sue Mahony, PhD to Board of Directors INDIANAPOLIS, December 18, 2017 - Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infe
Read more →ASMBAssembly Biosciences to Present at the Jefferies London Healthcare Conference
INDIANAPOLIS, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders ass
Read more →ASMBAssembly Biosciences Announces Pricing of $60 Million Offering of Common Stock
INDIANAPOLIS, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) (“Assembly” or the “Company”), a clinical-stage biotechnology company advancing a new class of oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel ora
Read more →ASMBAssembly Biosciences Announces Proposed Underwritten Offering of Common Stock INDIANAPOLIS
Biosciences Announces Proposed Underwritten Offering of Common Stock INDIANAPOLIS, Nov. 01, 2017 (GLOBE NEWSWIRE) - Assembly Biosciences, Inc. (NASDAQ: ASMB) ("Assembly" or the "Company"), a clinical-stage biotechnology company advancing a new class of oral therapeutic candid
Read more →ASMBAssembly Biosciences Announces 2017 AASLD Presentations
INDIANAPOLIS, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders ass
Read more →ASMBAssembly Biosciences, Inc. Corporate Presentation
Assembly Biosciences, Inc. Corporate Presentation September 26, 2017 Nasdaq: ASMB 1 Cautionary Note Regarding Forward - looking Statements The information in this presentation contains estimates and other forward - looking statements regarding future events, including statements
Read more →ASMBAssembly Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical Development Indianapolis, IN
Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical Development Indianapolis, IN, September 25, 2017 - Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of
Read more →ASMBAssembly Biosciences Announces September Conference Participation
INDIANAPOLIS, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders ass
Read more →ASMBAssembly Biosciences Announces June Conference Presentations
INDIANAPOLIS, May 26, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders asso
Read more →ASMBAssembly Biosciences Announces the Closing and Early Termination of Hart-Scott-Rodino Waiting Period for License of Microbiome Gastrointestinal Development Programs to Allergan
INDIANAPOLIS, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders ass
Read more →ASMBAssembly Biosciences Announces Successful Completion of ABI-H0731 Phase 1a Trial and Upcoming Conference Presentations
INDIANAPOLIS, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders ass
Read more →ASMBAssembly Biosciences, Inc.
Assembly Biosciences, Inc. Corporate Presentation January 2017 Nasdaq: ASMB Cautionary note r egarding forward - looking s tatements The information in this presentation contains estimates and other forward - looking statements regarding future events, including statements about
Read more →ASMBALLERGAN ASSEMBLY INVESTORS: INVESTORS: Lisa DeFrancesco Lauren Glaser (862) 261-7152 (415) 521-3828 MEDIA: MEDIA: Mark Marmur Barbara Lindheim (862) 261-7558 (212) 584-2276 Allergan Enters Into Licensing Ag
ALLERGAN ASSEMBLY INVESTORS: INVESTORS: Lisa DeFrancesco Lauren Glaser (862) 261-7152 (415) 521-3828 MEDIA: MEDIA: Mark Marmur Barbara Lindheim (862) 261-7558 (212) 584-2276 Enters Into Licensing Agreement with Assembly Biosciences to Obtain Worldwide Rights to Microbiom
Read more →ASMBAssembly Biosciences to Present Data on ABI-H0731 at AASLD 2016 Liver Meeting
INDIANAPOLIS, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biotherapeutics for disorders associat
Read more →ASMBAssembly Biosciences, Inc. Corporate Presentation November 2016 Cautionary note r egarding forward - looking s tatements The information in this presentation contains estimates and other forward - looking statements rega
Assembly Biosciences, Inc. Corporate Presentation November 2016 Cautionary note r egarding forward - looking s tatements The information in this presentation contains estimates and other forward - looking statements regarding future events, including statements about the therape
Read more →ASMBAssembly Biosciences Initiates Phase 1 Clinical Program of ABI-H0731 for Treatment of Chronic Hepatitis B Virus Infection
INDIANAPOLIS, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biotherapeutics for disorders associat
Read more →ASMBAssembly Biosciences Announces Key Additions to Microbiome Team
INDIANAPOLIS, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing novel oral therapeutics for disorders associated with the human microbiome and the treatment of hepatitis B virus (HBV) infection, today announced new sen
Read more →ASMBAssembly Biosciences Announces Participation in HBV Scientific Meetings in China and South Korea
INDIANAPOLIS, Sept. 21, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biological therapeutics for disorders associated wit
Read more →ASMBAssembly Biosciences to Present at the Jefferies 2016 Global Healthcare Conference
NEW YORK, June 01, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biological therapeutics addressing disorders associated w
Read more →ASMBAssembly Biosciences to Present Data at The International Liver Congress(TM) 2016 that Supports Advancing Its CpAM Candidates into HBV Clinical Trials
—In Preclinical Studies, Novel Class of Core Protein Allosteric Modifiers (CpAMs) Showed Potent Antiviral Activity, No Cytotoxicity and Good Pharmacokinetic Properties— —Planning to Start Phase 1 Trials in 2H16 While Also Advancing Additional CpAM Compounds— BARCELONA, Spain an
Read more →ASMBAssembly Biosciences to Present Data on New Series of HBV Core Protein Allosteric Modifiers at The International Liver Congress™ 2016
BARCELONA, Spain and NEW YORK, March 30, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic therapeutics for addressing the gut microbiome and new approaches to discovering drugs for the treatme
Read more →ASMBAssembly Biosciences Nasdaq: ASMB February 2016 RBC Capital Markets 2016 Healthcare Conference
Assembly Biosciences Nasdaq: ASMB February 2016 RBC Capital Markets 2016 Healthcare Conference C autionary Note Regarding Forward - Looking Statements The information in this presentation contains estimates and other forward - looking statements regarding future events, includin
Read more →ASMBAssembly Biosciences to Webcast Upcoming Investor Conferences
INDIANAPOLIS, Feb. 19, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a public biotechnology company advancing a new class of oral biologic drugs for addressing the gut microbiome and new approaches to discovering drugs for the treatment of hepatitis B virus (
Read more →ASMBAssembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel(TM) Technology Achieves Targeted Delivery to the Lower GI Tract
PHILADELPHIA and INDIANAPOLIS, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI), today reported that Mohan Kabadi, PhD, Assemb
Read more →ASMBAssembly Biosciences Nasdaq: ASMB January 2016 C autionary Note Regarding Forward - Looking Statements The information in this presentation contains estimates and other forward - looking statements regarding future event
Assembly Biosciences Nasdaq: ASMB January 2016 C autionary Note Regarding Forward - Looking Statements The information in this presentation contains estimates and other forward - looking statements regarding future events, including statements about the therapeutic potential of
Read more →ASMBAssembly Biosciences Expands Senior Leadership Team
INDIANAPOLIS, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, today announced several new senior level h
Read more →ASMBAssembly Biosciences appoints biotech veteran alan j. lewis to board of directors Indianapolis, IN
Biosciences appoints biotech veteran alan j. lewis to board of directors Indianapolis, IN, December 21, 2015 - Assembly Biosciences, Inc. (NASDAQ: ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. dif
Read more →ASMBAssembly Biosciences to Present at Jefferies Microbiome Summit
INDIANAPOLIS, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing curative treatments for infectious diseases including hepatitis B virus (HBV) and C. difficile (CDI) infections, announced that the company will participat
Read more →ASMBAssembly Biosciences to Describe Improved Methods for HBV Drug Development at Major International Meeting
—Data to Be Presented at 2015 International Meeting on the Molecular Biology of Hepatitis B Describes Improved Methods for Measuring Key Biomarkers for Curative Therapies— —Assembly Also Reporting New Peer-Reviewed Publication Highlighting Key Role of HBV Core Protein— NEW YORK
Read more →ASMBAssembly Biosciences Discusses Mechanism of Action of Its HBV Antiviral Program at 2nd ANRS HBV Cure Workshop -Workshop Sponsored by French National Agency for Research on AIDS and Viral Hepatitis - New York, New York, a
Assembly Biosciences Discusses Mechanism of Action of Its HBV Antiviral Program at 2nd ANRS HBV Cure Workshop by French National Agency for Research on AIDS and Viral Hepatitis - New York, New York, and Paris, France, May 19, 2015 - Assembly Biosciences, Inc. (NASDAQ: ASMB) t
Read more →ASMBAssembly Biosciences Announces Pricing of $75 Million Public Offering of Its Common Stock
NEW YORK, March 19, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) ("Assembly") announced today the pricing of an underwritten public offering of $75 million, or 5,555,555 shares of its common stock pursuant to an effective shelf registration statement that was
Read more →ASMBAssembly Biosciences February 2015 1 Forward - Looking Statements This presentation contains forward - looking statements regarding future events. Forward - looking statements involve known and unknown risks that could c
Assembly Biosciences February 2015 1 Forward - Looking Statements This presentation contains forward - looking statements regarding future events. Forward - looking statements involve known and unknown risks that could cause actual results to differ materially from expected resu
Read more →ASMBAssembly Biosciences to Present at 2015 RBC Capital Markets Healthcare Conference
NEW YORK, Feb. 20, 2015 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) today announced that it is participating in the 2015 RBC Capital Markets Healthcare Conference at the New York Palace Hotel in New York City. Assembly's Chief Executive Officer Derek Small and Ch
Read more →ASMBAssembly Biosciences Announces Senior Management Changes -Assembly Co-Founder Derek Small Named CEO, William Ringo Appointed Chairman, Current CFO David Barrett Adds COO Responsibilities- New York, New York
Assembly Biosciences Announces Senior -Assembly Co-Founder Derek Small Named CEO, William Ringo Appointed Chairman, Current CFO David Barrett Adds COO Responsibilities- New York, New York, February 17, 2015 - Assembly Biosciences, Inc. (NASDAQ: ASMB) today announced a number
Read more →ASMBAssembly Biosciences to Present at Investor Conferences
NEW YORK, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) today announced that it is participating in two investor conferences this week. The company has been invited to join a Hepatitis B Virus panel at the 26th Annual Piper Jaffray Healthcare Conferenc
Read more →ASMBAssembly Biosciences Announces $15.75 Million Registered Direct Offering New York, New York
Assembly Biosciences Announces $15.75 Million Registered Direct Offering New York, New York, October 1, 2014 - Assembly Biosciences, Inc. (Assembly) (ASMB) announced today that on October 1, 2014, it entered into an agreement with institutional investors for the sale of 1,959
Read more →ASMBAssembly Biosciences August 2014 This presentation contains forward - looking statements regarding future events. Forward - looking statements involve known and unknown risks that could cause actual results to differ mat
Assembly Biosciences August 2014 This presentation contains forward - looking statements regarding future events. Forward - looking statements involve known and unknown risks that could cause actual results to differ materially from expected results. These risks and uncertaintie
Read more →ASMBASSEMBLY BIOSCIENCES PROVIDES UPDATE ON STATUS OF VEN 307 (NEW YORK, NEW YORK) JULY 25, 2014 - Assembly Biosciences, Inc. (NASDAQ: ASMB), a biopharmaceutical company developing innovative treatments for hepatitis B virus
BIOSCIENCES PROVIDES UPDATE ON STATUS OF VEN 307 (NEW YORK, NEW YORK) JULY 25, 2014 - Assembly Biosciences, Inc. (NASDAQ: ASMB), a biopharmaceutical company developing innovative treatments for hepatitis B virus (HBV) and C. difficile-associated diarrhea (CDAD,) today announce
Read more →ASMBAssembly Biosciences Provides Update on Status of VEN 307
NEW YORK, July 25, 2014 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB), a biopharmaceutical company developing innovative treatments for hepatitis B virus (HBV) and C. difficile-associated diarrhea (CDAD,) today announced that it will not pursue further development
Read more →ASMBVentrus Biosciences Becomes Assembly Biosciences as Stockholders Approve Merger with Assembly Pharmaceuticals, Inc. Stockholders Approve Issuance of Common Stock in Connection with the Merger, a Reverse Stock Split and C
Biosciences Becomes Assembly Biosciences as Stockholders Approve Merger with Assembly Pharmaceuticals, Inc. Approve Issuance of Common Stock in Connection with the Merger, a Reverse Stock Split and Company Name Change YORK, JULY 14, 2014 (GLOBE NEWSWIRE) -- Ventrus Biosciences,
Read more →ASMBVENTRUS BIOSCIENCES TO MERGE WITH ASSEMBLY PHARMACEUTICALS ~ New Company, Assembly Biosciences, to Focus on First-in Class Technology for Treatment and Potential Cure of Hepatitis B Virus Infection, Affecting 350 Million
BIOSCIENCES TO MERGE WITH ASSEMBLY PHARMACEUTICALS New Company, Assembly Biosciences, to Focus on First-in Class Technology for Treatment and Potential Cure of Hepatitis B Virus Infection, Affecting 350 Million Worldwide Projected Multi-Billion Market Opportunity; No Curative
Read more →ASMBVentrus Biosciences Receives Date for Type B pre-NDA Meeting with FDA for DOLIZEM (Diltiazem Hydrochloride Cream) in Anal Fissures
Ventrus Biosciences Receives Date for Type B pre-NDA Meeting with FDA for DOLIZEM (Diltiazem Hydrochloride Cream) in Anal Fissures NEW YORK, April 4, 2014 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq: VTUS), a pharmaceutical company focused on developing and commercia
Read more →ASMBVentrus Biosciences Announces Results from Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients with Anal Fissure VEN 307 efficacy as expected; placebo effect greater than anticipated, resulting in no si
Ventrus Biosciences Announces Results from Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients with Anal Fissure NEW YORK, February 12, 2014 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today announced top line efficacy and safety results from
Read more →ASMBForward Looking Statements This material contains estimates and forward - looking statements. The words "believe," "may," "might," "will," "aim," "estimate," "continue," "would," "anticipate, ""intend," "expect," "plan"
Forward Looking Statements This material contains estimates and forward - looking statements. The words "believe," "may," "might," "will," "aim," "estimate," "continue," "would," "anticipate, ""intend," "expect," "plan" and similar words are intended to identify estimates and for
Read more →ASMBVENTRUS BIOSCIENCES COMPLETES ENROLLMENT OF SECOND PIVOTAL PHASE 3 TRIAL OF DILTIAZEM CREAM (VEN 307) IN PATIENTS WITH ANAL FISSURE Results Expected First Quarter 2014; NDA Filing Expected to Occur in Second Quarter 2014
COMPLETES ENROLLMENT OF SECOND PIVOTAL PHASE 3 TRIAL OF DILTIAZEM CREAM (VEN 307) IN PATIENTS WITH ANAL FISSURE First Quarter 2014; NDA Filing Expected to Occur in Second Quarter 2014 25, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced that it has com
Read more →ASMBVENTRUS BIOSCIENCES ANNOUNCES POSITIVE RESULTS FROM CLINICAL DERMAL SAFETY AND PHARMACOKINETIC STUDIES OF DILTIAZEM (VEN 307) Results from Second Pivotal Phase 3 Trial in Anal Fissures Expected First Quarter 2014 NEW YOR
ANNOUNCES POSITIVE RESULTS FROM CLINICAL DERMAL SAFETY AND PHARMACOKINETIC STUDIES OF DILTIAZEM (VEN 307) Second Pivotal Phase 3 Trial in Anal Fissures Expected First Quarter 2014 NEW YORK, SEPT 11, 2013 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceu
Read more →ASMBVENTRUS BIOSCIENCES ANNOUNCES FULL EXERCISE OF OVERALLOTMENT OPTION BY UNDERWRITERS New York, NY
VENTRUS BIOSCIENCES ANNOUNCES FULL EXERCISE OPTION BY UNDERWRITERS New York, NY, February 7, 2013 - Ventrus Biosciences, Inc. (Nasdaq: VTUS) today announced that the underwriter of its previously announced public offering of common stock has exercised in full its overallotmen
Read more →ASMBVENTRUS BIOSCIENCES ANNOUNCES $20 MILLION FINANCING New York, NY
VENTRUS BIOSCIENCES ANNOUNCES $20 MILLION New York, NY, January 30, 2013 - Ventrus Biosciences, Inc. (Nasdaq: VTUS) announced today the pricing of concurrent, separate underwritten offerings of (i) 5,800,000 shares of its common stock at a price to the public of $2.50 for each
Read more →ASMBThis material contains estimates and forward - looking statements. The words "believe," "may," "might," "will," "aim," "estimate," "continue," "would," "anticipate, ""intend," "expect," "plan" and similar words are inten
1 This material contains estimates and forward - looking statements. The words "believe," "may," "might," "will," "aim," "estimate," "continue," "would," "anticipate, ""intend," "expect," "plan" and similar words are intended to identify estimates and forward - looking statements
Read more →ASMBVENTRUS BIOSCIENCES RECEIVES FDA WRITTEN FEEDBACK, TARGETS NDA FILING FOR DILTIAZEM (VEN 307) IN ANAL FISSURES FOLLOWING SECOND PHASE 3 STUDY NDA Filing Expected to Occur in Fourth Quarter 2013 Company to Host Conference
RECEIVES FDA WRITTEN FEEDBACK, TARGETS NDA FILING FOR DILTIAZEM (VEN 307) IN ANAL FISSURES FOLLOWING SECOND PHASE 3 STUDY Expected to Occur in Fourth Quarter 2013 Host Conference Call and Presentation Today, November 5, at 10:00 a.m. ET 5, 2012 -- Ventrus Biosciences, Inc. (N
Read more →ASMBSLIDE PRESENTATION 1 This material contains estimates and forward - looking statements. The words "believe," "may," "might," "will," "aim," "estimate," "continue," "would," "anticipate, ""intend," "expect," "plan" and si
1 This material contains estimates and forward - looking statements. The words "believe," "may," "might," "will," "aim," "estimate," "continue," "would," "anticipate, ""intend," "expect," "plan" and similar words are intended to identify estimates and forward - looking statements
Read more →ASMBVENTRUS BIOSCIENCES ANNOUNCES RESULTS FROM PIVOTAL PHASE 3 TRIAL OF IFERANSERIN (VEN 309) IN PATIENTS WITH HEMORRHOIDAL DISEASE Company to Host Conference Call Today, June 25, at 9:00 a.m. ET NEW YORK, JUNE 25, 2012 (GLO
BIOSCIENCES ANNOUNCES RESULTS FROM PIVOTAL PHASE 3 TRIAL OF IFERANSERIN (VEN 309) IN PATIENTS WITH HEMORRHOIDAL DISEASE Host Conference Call Today, June 25, at 9:00 a.m. ET YORK, JUNE 25, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today reported that its
Read more →ASMBRussell H. Ellison, MD, MSc Chief Executive Officer and Chairman of the Board 1 This material contains estimates and forward - looking statements. The words "believe," "may," "might," "will," "aim," "estimate," "continue
Russell H. Ellison, MD, MSc Chief Executive Officer and Chairman of the Board 1 This material contains estimates and forward - looking statements. The words "believe," "may," "might," "will," "aim," "estimate," "continue," "would," "anticipate, ""intend," "expect," "plan" and si
Read more →ASMBVENTRUS BIOSCIENCES ANNOUNCES POSITIVE RESULTS FROM PIVOTAL PHASE 3 TRIAL OF DILTIAZEM (VEN 307) IN PATIENTS WITH ANAL FISSURES Treatment Arms Show Significant Improvement Over Placebo in Three Major Outcomes Adverse Eve
ANNOUNCES POSITIVE RESULTS FROM PIVOTAL PHASE 3 TRIAL OF DILTIAZEM (VEN 307) IN PATIENTS WITH ANAL FISSURES Arms Show Significant Improvement Over Placebo in Three Major Outcomes Similar Between Treatment Arms and Placebo Host Conference Call and Presentation Today, May 14, a
Read more →ASMBVentrus Biosciences Completes Enrollment of Pivotal Phase 3 Trial of Iferanserin (VEN 309) in Patients With Hemorrhoidal Disease Results Are Anticipated in Late June to Early July - 2012
Ventrus Biosciences Completes Enrollment of Pivotal Phase 3 Trial of Iferanserin (VEN 309) in Patients With Hemorrhoidal Disease Results Are Anticipated in Late June to Early July - 2012 NEW YORK, April 30, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) ann
Read more →ASMBVentrus Announces Publication of Prior Phase 2b Study on the Safety and Efficacy of Iferanserin in the Treatment of Hemorrhoid Disease
Ventrus Announces Publication of Prior Phase 2b Study on the Safety and Efficacy of Iferanserin in the Treatment of Hemorrhoid Disease NEW YORK, January 13, 2011 -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), today announced the online publication of the prior Phase 2b study utiliz
Read more →ASMBVENTRUS BIOSCIENCES TO ANNOUNCE 3Q 2011 FINANCIAL RESULTS, CLINICAL UPDATE AND OMNIBUS MARKET RESEARCH RESULTS
VENTRUS BIOSCIENCES TO ANNOUNCE 3Q 2011 FINANCIAL RESULTS, CLINICAL UPDATE AND OMNIBUS MARKET RESEARCH RESULTS: CONFERENCE CALL AND WEBCAST NEW YORK, NY November 9, 2011 - Ventrus BioSciences, Inc. (Nasdaq: VTUS) announced today that it will report on its clinical trial progress
Read more →ASMBVentrus Biosciences Announces Exercise of Underwriters' Over-Allotment Option and Closing of $51.75 Million Underwritten Registered Offering
Ventrus Biosciences Announces Exercise of Underwriters' Over-Allotment Option and Closing of $51.75 Million Underwritten Registered Offering NEW YORK, July 19, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on devel
Read more →ASMBVentrus Biosciences Announces Pricing of Its Underwritten Registered Offering of Common Stock
Ventrus Biosciences Announces Pricing of Its Underwritten Registered Offering of Common Stock NEW YORK, July 14, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today
Read more →ASMBVENTRUS RECEIVES SPA RESPONSE FROM FDA AND WILL UPDATE AND FILE THE FIRST PIVOTAL TRIAL PROTOCOL TO ITS IND NEW YORK, NY JUNE 22, 2011 - Ventrus BioSciences, Inc. (Nasdaq: VTUS) announced today that it has received a res
VENTRUS RECEIVES SPA RESPONSE FROM FDA AND WILL UPDATE AND FILE THE FIRST PIVOTAL TRIAL PROTOCOL TO ITS IND NEW YORK, NY JUNE 22, 2011 - Ventrus BioSciences, Inc. (Nasdaq: VTUS) announced today that it has received a response from the U.S. Food and Drug Administration (FDA) to i
Read more →ASMBVentrus Receives Notice Of Allowance For U.S. Patent For VEN 307 U.S. Patent Office Allows Claims For 2% Diltiazem Cream For Treatment of Anal Fissures NEW YORK, NY -- Ventrus Biosciences, Inc. announced today that the c
Ventrus Receives Notice Of Allowance For U.S. Patent For VEN 307 U.S. Patent Office Allows Claims For 2% Diltiazem Cream For Treatment of Anal Fissures NEW YORK, NY -- Ventrus Biosciences, Inc. announced today that the claims in its currently pending U.S. Patent Application No
Read more →ASMBUnassociated Document
Unassociated Document
Read more →ASMBThis material contains estimates and forward looking statements, as defined by the Private Securities Litigation Reform Act of 1995. The words "believe," "may," "might," "will," "aim," "estimate," "continue," "would," "a
material contains estimates and forward looking statements, as defined by the Private Securities Litigation Reform Act of 1995. The words "believe," "may," "might," "will," "aim," "estimate," "continue," "would," "anticipate," "intend," "expect," "plan" and similar words are i
Read more →ASMBVentrus Completes Clinical Development Staffing
Completes Clinical Development Staffing Feb. 1, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the completion of its clinical development staffing.
Read more →ASMBUnderwriters Exercise Over-Allotment Option for Ventrus Biosciences' Initial Public Offering
Exercise Over-Allotment Option for Ventrus Biosciences' Initial Public Jan. 7, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that the u
Read more →Competitive Position
How ASMB ranks across every disease it competes inCompetitive Position is a premium feature
See how ASMB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial